Evercyte is a Vienna-based company founded in 2011 that provides human cell cultures for the establishment of relevant and standardisable in vitro cell based assays. Thus, Evercyte supports the 3R´s (replacement, reduction, refinement) principle and helps to avoid the use of cells that do not reflect tissue specific physiologies. This is achieved by extending the proliferative life span of cells either by reactivation of telomerase in human somatic cells or by reprogramming of urine-derived cells towards induced pluripotent stem cells.

Evercyte cell cultures also represent cell factories for manufacturing of complex biopharmaceuticals, whereby a focus has been put on production of extracellular vesicles (EVs, exosomes) that are currently evaluated for their therapeutic potential in tissue regeneration and as drug targeting vehicles.

Moreover, Evercyte as a CRO, develops customized human cell cultures and bioassays and offers testing of drug candidates for efficacy, potency or toxicity.